Header Logo

Connection

Constantinos Wibmer to Neutralization Tests

This is a "connection" page, showing publications Constantinos Wibmer has written about Neutralization Tests.
Connection Strength

1,042
  1. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625.
    View in: PubMed
    Score: 0,717
  2. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,135
  3. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
    View in: PubMed
    Score: 0,048
  4. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
    View in: PubMed
    Score: 0,045
  5. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
    View in: PubMed
    Score: 0,028
  6. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,025
  7. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol. 2012 May; 86(9):4989-99.
    View in: PubMed
    Score: 0,024
  8. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol. 2009 Sep; 83(17):8925-37.
    View in: PubMed
    Score: 0,020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.